鶹ý

How Many Ditch GLP-1 Drugs? More Weekly Insulin Data; Ozempic for Alcohol Use?

— News and commentary from the endocrinology world

MedpageToday
Endo Break over a computer rendering of a man with illustrated body organs.

At 12 months, 36.5% of in a study of nearly 200,000 adults with obesity with or without type 2 diabetes. (JAMA Network Open)

In a phase Ib trial, a of the dual GLP-1/GIP receptor agonist CT-388 led to a mean placebo-adjusted weight loss of 18.8% over 24 weeks, Genentech said.

A utilizing patient preference of weight management treatments significantly boosted clinically significantly weight loss in patients with obesity. This "model offers an alternative to the failed status quo in primary care-based obesity treatment," lead author Dina Griauzde, MD, MSc, of the University of Michigan Medical School in Ann Arbor, told 鶹ý. (JAMA Network Open)

Once-weekly in insulin-naive adults with type 2 diabetes reduced HbA1c levels by 1.34% compared with 1.26% for once-daily insulin degludec in the 52-week QWINT-2 trial. In the 26-week QWINT-4 trial, insulin efsitora alfa and insulin glargine both reduced HbA1c level by 1.07%, Eli Lilly announced.

Bariatric surgery was more effective than medical care at in women with polycystic ovary syndrome, obesity, and oligomenorrhea or amenorrhea. (The Lancet)

Nestlé is launching a new line of frozen foods for to lose weight. (CNN)

Novo Nordisk said it will start assessing (Ozempic, Wegovy) on alcohol consumption in a clinical trial. (CNN)

Compared with conventional glycemic control primarily through diet, with sulfonylurea, insulin, or metformin reduced the risks of myocardial infarction, microvascular disease, and death in type 2 diabetes. "Newer drugs can also help to reduce risk, likely in part via non-glucose-mediated pathways, but good glucose control from the get-go remains essential however this is achieved," study author Rury Holman, MBChB, of Churchill Hospital in England, told 鶹ý.

A Swedish study found that bariatric surgery was associated with a in women with obesity, with the greatest benefit in women with hyperinsulinemia. (JAMA Surgery)

, a digital pharmacy startup, announced that they will introduce access to compounded GLP-1 weight-loss injections. (CNBC)

Greater prenatal exposure to certain was linked to risk of metabolic syndrome in kids ages 6 to 11, a European cohort study indicated. (JAMA Network Open)

Eli Lilly to stop Totality Medispa from suggesting it sells Lilly's tirzepatide (Mounjaro, Zepbound) and from making certain claims about its compounded version of the drug.

Regardless of diabetes duration, of cardiovascular disease, lower limb and kidney complications, and diabetic retinopathy compared with women. (Journal of Epidemiology & Community Health)

A federal appeals court said a health insurance provider can be liable for to transgender people under the Civil Rights Act. (AP)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.